Investing in Ayala Pharmaceuticals, Inc. (ADXS)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)3.27Infinity
Intrinsic value (DCF)3.27Infinity
Graham-Dodd Method0.00NaN
Graham Formula0.00NaN

Company description

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.